Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
|Slideshows|February 3, 2020
- Vol 37, Issue 1
- Volume 37
- Issue 1
In This Issue of Psychiatric Times: Vol 37, No 1
Author(s)Laurie Martin
13 psychiatry stories you may have missed: A round-up of the latest issue of Psychiatric Times, all in one place, with a bonus PDF.
Advertisement
Articles in this issue
over 6 years ago
Celebrating Progress, but Challenges Remainover 6 years ago
Autoimmune Encephalitis: What Psychiatrists Need to Knowover 6 years ago
The Opening of the Maudsley Hospital: January 31, 1923over 6 years ago
Disaster Response, Mental Health, and Community Resilienceover 6 years ago
Psychiatrists Are Not the Retiring KindAdvertisement
Related to this article
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5